Skip to main content

Table 3 Concomitant medication at baseline in CVOTs referred to in the text

From: Current perspectives on cardiovascular outcome trials in diabetes

Concomitant medication @baseline Antihyperglycemic medication
N (%)
CV treatment
N (%)
Insulin Metformin Sulphonylurea Aspirin Statins Antiplatelet/anticoagulant Beta-blocker ACEI/ARB Other anti-hypertensives
SAVOR-TIMI53 6757 (40.9) 11,094 (67.4) 6332 (38.5) 12,390 (75.2) 12,892 (78.3) 13,386 (81.3) 10,117 (61.4) 12,935 (78.5) 6730 (40.9)
EXAMINE 1605 (29.8) 3562 (66.2) 2503 (69.9) 4881 (90.7) 4866 (90.4) 5232 (97.2) 4411 (81.9) 4411 (81.9) 1197 (22.2)
TECOS 3408 (23.2) 11,966 (81.6) 6645 (45.3) 11,518 (78.5) 11,719 (79.9) 3167 (21.7) 9322 (63.5) 11,555 (78.8) 4961 (33.8)
ELIXA 2292 (37.8) 3834 (63.2) 1863 (30.7) 5726 (94.4) 5621 (92.6) 480 (7.9) 5119 (84.4) 5151 (84.9) 1327 (21.9)
EMPA-REG OUTCOME 2394 (34)a 3933 (55.9)a 1383 (19.6) 5990 (85) 5387 (77) 4537 (64) 5651 (80) 2114 (30)
LEADER 3905 (41.8)a 7136 (76.4) 4721 (50) 6523 (69.8) 6729 (72) 6322 (67.7) 5173 (55.4) 4761 (51) 920 (9.85)
SUSTAIN-6 1913 (58.0) 2414 (73.2) 1410 (42.8) 2108 (63.9) 2399 (72.8) 406 (12.3) 1894 (57.4) 1642 (49.8) 258 (7.8)
CAROLINA 4982 (82.5) 1728 (28.6) 3026 (50.1) 3872 (64.1) 2344 (38.8) 2664 (44.1) 1770 (29.3)
CANVAS 2171 (50.1) 3158 (72.9) 2032 (46.9)   3119 (72.0) 3073 (71.0)    
  1. aBoth mono and dual therapy